10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Thursday, August 18, 2011

Aanjaneya Lifecare Ltd:-Buy/sell/,growth prospects and recommendation,news and results,target price and analysis,view and outlook,multibagger

Scripscan:Aanjaneya Lifecare Ltd

Story:Promoted by Dr Kannan Kashi Vishwanath, Anjaneya Lifecare has manufacturing and marketing capabilities in API (active pharmaceutical ingredients) with focus on anti-malarial, and finished dosage forms (FDFs).The company's present product portfolio consists of second generation, quinine based anti malarial APIs and third generation artemisinin based antimalrial APIs, niche APIs and FDFs. Further, it has set up a dedicated small R&D block in Mahad, Maharastra, for producing highly potent anti cancer products.Presently, the company is supplying APIs and FDFs both domestically and exporting to around 15 countries. With the expansion of existing facility and the acquisition of the formulation unit at Pune FDFs, shall be marketed in domestic and international markets as branded generics. In finished dosages it will cover important therapeutic segments such as anti-malarial, pain management, erectile dysfunction and hormone replacement therapy, anti obesity and herbal supplements in syrup and tablet form amongst others. It also supplies as contract manufacturer in formulation segment to Wockhardt, Cipla, and Glenmark Pharmaceuticals. Interestingly, It has 5 patents registered in India and acquired rights for three patent applications (gemicitabine hydrochloride, capacitabine and docetaxel).The company was primarily a bulk drug player, and it ventured into formulation business only in April 2010, which stepped up only after acquisition made in October 2010. Bulk drug players generally command very low discounting in markets, unless they get sizeable portion of revenues from advanced markets.Sizeable portion of the company's revenues from domestic markets, and that too as a contract manufacturer to other domestic pharma companies. The company is relatively a very small player in the Indian pharmaceutical market.It is still over dependant on anti-malarial segment.Cash flow from operating activities was negative Rs 21.93 crore in FY 2009 and negative Rs 39.28 crore in the 10 months ended January 2011.At present prices its quoting over 20 P.E its forward earnings which is very high for a relatively tiny player.Sell and move on to better pharma bets.

No comments:

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner